Hyperpolarized 13C-pyruvate for metabolic syndrome

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 Oct 2024: Trial registered, NCT06645691
  2. 17 Oct 2024: Trial started, NCT06645691

The trials

NCT06645691: Hyperpolarized MR Imaging With Carbon-13 Pyruvate in the Human Body

State
Under way
Phase
Phase 2
People
200 planned
Started
17 Oct 2024
Primary completion
31 May 2028
Arms
Hyperpolarized Pyruvate [13C] Injection
Results
None posted
  1. 17 Oct 2024: Trial registered
  2. 17 Oct 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.